Development of novel radioligands improves imaging of tauopathies, highlighting advances beyond Alzheimer's disease.
Tauopathies are a heterogeneous group of neurodegenerative diseases characterized by the pathological accumulation of microtubule-associated protein tau filaments in the brain. The development of tau-targeted positron emission tomography (PET) tracers has facilitated in vivo mapping and quantification of this pathological biomarker, particularly in Alzheimer's disease (AD). Recent efforts have expanded toward the development of radioligands for imaging non-AD tauopathies, which are critical for advancing diagnosis and understanding disease mechanisms across the broader spectrum of tau-related neurodegeneration.
No takes yet. Share an insight, caveat, or question.
Steven H. Liang (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: